SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions is trending due to a strategic manufacturing partnership with Syrma Johari MedTech, which aims to scale production of its fingerprinting drug screening reader and anticipates substantial cost savings. This positive news, however, is being overshadowed by a significant private placement and share offering that has fueled community concerns over potential dilution. Traders are actively debating the impact of this offering on the stock's recent volatility and future price trajectory.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as its community eagerly anticipates the start of a new yearly cycle, with many predicting a significant bullish reversal based on historical performance. Investors are discussing aggressive accumulation, forecasting substantial long-term growth and positioning LTC as a strong contender for major appreciation in upcoming crypto market upturns.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is experiencing significant momentum driven by its extremely low share float, fueling widespread community discussion around its potential for a short squeeze. Traders are actively accumulating shares, anticipating a parabolic breakout and new highs as volume continues to build, drawing comparisons to other recent volatile low-float stocks.

Alchemy Investments Acquisition Corp. 1 is a blank check company, which engages in merger, share exchange, asset acquisition, share purchase, and reorganization or similar business combination. The company was founded on October 27, 2021 and is headquartered in Newark, DE.

Alchemy Investments Acquisition Corp 1 - Ordinary Shares - Class A

Alchemy Investments Acquisition Corp 1 (ALCY) is actively trending as the community speculates it could be the next low-float SPAC to experience a substantial price surge, drawing parallels to recent strong performers like ESHA. Traders are enthusiastically discussing a potential significant move, driven by the broader "low float SPAC bubble" theme and the perceived ease of high-percentage gains. This collective anticipation is fueling positioning and elevated trading activity.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending as a low-float SPAC, sparking widespread community discussion about its potential for explosive upward movement. Traders are actively debating whether it will follow the recent parabolic runs seen in similar micro-float companies, with many advocating for holding positions amid high volatility. The conversation emphasizes the stock's thin order book and the perceived impact of high insider ownership on its price action.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending upward following significant regulatory updates, including the FDA's priority review of AXS-05 for Alzheimer's disease agitation and positive feedback supporting an NDA submission for AXS-12 in narcolepsy. The community is buzzing with excitement, celebrating these milestones as pivotal catalysts that could drive substantial market expansion and propel the company toward future growth, particularly given the high impact of Alzheimer's-related treatments.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai (BBAI) is actively trending following the announced completion of its Ask Sage acquisition, a strategic move aimed at enhancing its secure generative AI capabilities for government and regulated industries. This development is sparking community discussion around its potential to secure significant government contracts, particularly for defense and airport security, amidst ongoing debates regarding upcoming shareholder votes on dilution and the stock's future trajectory within the AI-driven government tech sector.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending after announcing $10 million in new autonomous systems orders, a key catalyst driving significant bullish sentiment among investors. The community is buzzing with optimism about the company's strong position in the growing global counter-drone and autonomous defense sectors, anticipating further substantial contract awards and growth in 2026. This positive outlook is further bolstered by the recent launch of a 2x long ETF specifically tracking ONDS.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is a top trending stock, buoyed by the recent confirmation of China's extended EV trade-in subsidies into 2026 and strong anticipation for December delivery figures and potential Q4 profitability. Bulls are highly optimistic, pointing to significant operational growth, strategic wins like the Onvo L90 police vehicle program, and an expanding battery swap network as indicators of an imminent breakout, while many perceive current price action as manipulation. Conversely, skeptics express frustration over the stock's historical volatility and a lack of sustained gains, questioning its path to consistent profitability in China's competitive EV market.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending with high anticipation ahead of Anaphylm's pivotal FDA decision on January 31, 2026, for its novel, device-free epinephrine film. Community discussion is vibrant, with many confident in approval citing strong clinical data and a waived advisory committee, while others express caution due to historical regulatory setbacks and a notable short interest. The market keenly watches if Anaphylm will significantly disrupt the existing anaphylaxis treatment landscape, challenging rivals like SPRY.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lululemon founder Chip Wilson speaks during WE Day at KeyArena on April 21, 2017 in Seattle, Washington.

Proxy Battles Exploded In 2025 — And Lululemon’s Founder Is Making A Final Power Play

This year witnessed more boardroom battles than ever, with Lululemon becoming the latest to see a fight as the year comes to a close.

Equity

This year witnessed more boardroom battles than ever, with Lululemon becoming the latest to see a fight as the year comes to a close.


Can NIKE's "Sport Offense" Reignite Growth Across Key Markets?

NKE is betting on its Sport Offense sport-led innovation and faster cycles to rebuild brand heat, fix channels and reignite growth across key markets.

Wholesale Strength vs. Digital Strain: Is NIKE's Channel Mix Working?

NKE's wholesale rebound is lifting revenues, but digital sales are lagging as promotions fade and traffic softens, raising doubts about channel balance.

Can NIKE's Digital Expansion Strategy Reignite Consumer Engagement?

NKE's digital engine still engages consumers, but fewer promotions have hit traffic and sales, leaving the Direct channel under pressure.

<ul class="summary-bullets"><li>Nike will report its fiscal 2026 second-quarter earnings after the market close on Thursday, with analysts expecting a topline decline.</li><li>After a strong Q1 report in September, expectations that Nike will keep the turnaround momentum going are high.</li><li>Under CEO Elliott Hill, Nike needs to show significant progress across key measures, including inventory levels, the product roadmap, and its China business.</li></ul>Nike’s second-quarter earnings report after the market close on Thursday is largely expected to show a “stable” business with moderate improvements from the ongoing turnaround under CEO Elliott Hill, analysts say.&nbsp;Although the sentiment is more optimistic than glum, at least among Stocktwits users, for Nike to hit a home run, it has to show progress on at least these three fronts: inventory cleanup, new products, and its China business.Nike delighted Wall Street after posting top-line growth in its fiscal 2026 first quarter – its first in six quarters – sending the stock higher in October, with analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nike-analysts-positive-after-q1-outperformance-retail-stays-bullish/chCAxA1R3Oe">hailing</a> that “the turnaround is well underway” and the "sleeping bear awakens."But, with Nike’s stock still down nearly 14% year-to-date, investors are looking for more. The company's Q2 results will likely "represent an inflection," where it would likely move beyond "at least some internal disruptions," Oppenheimer analysts said in a recent note. &nbsp;<figure class="image"><img style="aspect-ratio:1400/1200;" src="https://news.stocktwits-cdn.com/koyfin_20251218_025610313_png_4eb95d79d4.webp" alt="koyfin_20251218_025610313.png" width="1400" height="1200"></figure> Now more than a year in the CEO role, Hill needs to show sustained gains. His turnaround plan centers on pivoting Nike to excel in top-of-the-line sportswear and improving the company’s sales and distribution. Under the plan, he has shaken up top management, trimmed the workforce, returned to direct selling on Amazon, and struck partnerships (<a href="https://stocktwits.com/news-articles/markets/equity/nike-stock-surges-on-skims-tie-up-retail-bulls-see-big-boost-from-kim-kardashian/ch5rNxlRvu">Nike-Skims</a>, and the Faith Kipyegon a-mile-under-a-minute&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nike-aims-to-sprint-back-into-running-spotlight/chQnDrTRbgx">challenge</a>, to name a few) to reposition Nike as a brand for elite athletes.<h2 class="st-heading-2">Inventory Cleanup</h2>Over the last few years, Nike has built up excess due to supply chain disruptions in the aftermath of the COVID-19 pandemic and Nike’s erstwhile focus on lifestyle wear and shoes. Last quarter, the company reported a 2% drop in inventory levels, and Hill said Nike had stabilized inventory of Air Force 1 and Air&nbsp;Jordan sneakers but still had excess Nike Dunks.&nbsp; &nbsp;<figure class="image"><img style="aspect-ratio:1600/1133;" src="https://news.stocktwits-cdn.com/Nike_Is_Clearing_The_Investory_Buildup_For_New_Products_jpg_6568b0b31c.webp" alt="Nike_Is_Clearing_The_Investory_Buildup_For_New_Products.jpg" width="1600" height="1133"></figure> Analysts have flagged that healthy inventory levels are essential as Nike makes space for new launches, including the Nike Mind shoe collection and Aero-Fit cooling technology.<h2 class="st-heading-2">New Products</h2>Hill's predecessor, John Donahoe, focused Nike heavily on lifestyle products, which the company is now trying to undo. Hill has said that Nike is returning to its focus on sports, namely running and basketball, as it seeks to regain ground lost to brands like On Holdings, Asics, Under Armour, and Adidas.Nike would likely discuss upcoming launches, which would also be key given a strong sporting calendar next year, including the FIFA World Cup and the Winter Olympics. Sportswear sales typically spike during&nbsp;major tournaments, and brands use this period to launch event-focused and signature collections.<h2 class="st-heading-2">The China Problem</h2>Although North America is Nike's key market, part of its rebound hinges on China. Sales in the region had lagged of late, and analysts see little to no change in the situation. Nike’s sales in China tumbled 10% to $1.51 billion in Q1 – the figure is at the low end historically – and Hill blamed “structural challenges” in the market. China accounts for about one-fifth of Nike’s total revenue. &nbsp;<figure class="image"><img style="aspect-ratio:1600/1133;" src="https://news.stocktwits-cdn.com/Nikes_China_Sales_Have_Declined_For_Five_Consecutive_Quarters_jpg_dd38d82583.webp" alt="Nikes_China_Sales_Have_Declined_For_Five_Consecutive_Quarters.jpg" width="1600" height="1133"></figure> On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/NKE">NKE</a> has been climbing this month and was ‘extremely bullish’ in the last reading, with users broadly expecting a strong earnings report.&nbsp;Analysts expect Nike’s Q2 revenue to decline 1.2% to $11.41 billion, and adjusted per share earnings to decline 13.4% to $0.47, according to consensus estimates from Koyfin. About two-thirds of analysts covering Nike recommend a ‘Buy’ or higher.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

The Nike logo outside a store on the Fifth Avenue in New York City. U.S. (Photo by Zamek/VIEWpress)

Nike’s Earnings Test: 3 Things Investors Need To See For A Real Turnaround

After a strong Q1 report in September, investors and analysts are looking for another solid showing to confirm that the turnaround is delivering tangible gains.

The Zacks Analyst Blog NIKE, Steven Madden,  Wolverine World Wide and Adidas'

NKE heads into Q2 earnings with declining sales and margins expected, even as its ???Win Now??? turnaround shows early regional progress.

NIKE Pre-Q2 Earnings: Buy Now or Wait Out Near-Term Volatility?

NKE heads into Q2 earnings with expected y/y revenue and EPS declines, as margin pressure and China weakness test its "Win Now" turnaround.

5 Shoes & Retail Apparel Stocks to Watch as Cost Pressures Persist

The Shoes & Retail Apparel industry faces rising costs and soft demand, yet innovation, strong e-commerce gains and wellness-driven trends keep players like NKE, ADDYY, SHOO, WWW and CAL positioned for long-term growth. 

Running Strong, Sportswear Soft: Can NIKE Balance Its Portfolio?

NKE posts strong running gains, but lingering Sportswear and China weaknesses pose challenges as its brand trio aims to regain full momentum.

NIKE Stock Falls 11% in 3 Months: A Buy Opportunity or Value Trap?

NKE's three-month slide, digital slowdown and margin strain put the stock at a crossroads as investors weigh rebound potential against mounting headwinds.

adidas AG engages in the design, distribution, and marketing of athletic and sporting lifestyle products. It operates through the following geographical segments: EMEA, North America, Greater China, Asia-Pacific, Latin America, and Other Businesses. The Other Businesses segment includes the activities of the Y-3 label and other subordinated businesses. The company was founded by Adolf Dassler in 1920 and is headquartered in Herzogenaurach, Germany.

Current Price	$98.85
Prev Close	$99.50
Open	$98.85
Dividend Yield	0.64%
50-Day Moving Average	$96.32
Beta	1.01
Avg. Volume	88,585.74
PE Ratio	26.02

52-Week High	$137.73
52-Week Low	$86.28
Market Capitalization	$35.53B
EPS (Annual)	$2.31
Price to Book	5.31
Revenue Per Employee	$412,955.30
Enterprise Value/EBITDA	N/A

ADDYY
Adidas

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ADDYY News

ADDYYAdidas